CSIMarket Company Name, Ticker, Customers, else..
Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)
Other Ticker:  
 


 

Aurinia Pharmaceuticals Inc

AUPH's Financial Statements and Analysis



Aurinia Pharmaceuticals Inc reported in the third quarter of 2025 net earnings per share of $0.23 an increase by 130 % year on year from $0.10 and an improvement of 43.75 % from $0.16 realized in II. Quarter (Jun 30 2025).


third quarter of 2025
Earnings Per Share Revenues
$ 0.23 $  73 Mill
$+0.13     +130 % $+6M     +8.41 %



Aurinia Pharmaceuticals Inc 's Revenue rose by 8.41 % in third quarter of 2025 (Sep 30 2025) year on year, to $73 million and advanced by 4.94 % sequentially.


Aurinia Pharmaceuticals Inc is

More on AUPH's Income Statement



Aurinia Pharmaceuticals Inc 's net income of $31.551 million in the third quarter of 2025 increased by 119.87 % from net earnings of $14.350 million achieved in III. Quarter a year ago.

Sequentially net earnings grew by 46.66 % from net income of $21.513 million realized in previous quarter.

More on AUPH's Growth

Aurinia Pharmaceuticals Inc Inventories
Inventories grew by 15.7 % to $45 million from III. Quarter a year ago, sequentially inventories fell by -3.68 %. AUPH's Cash flow In the third quarter of 2025 company's net cash flow was $20 million, capital expenditures grew by -0.129-49.61%, to $0 millions compare to same quarter a year ago

More on AUPH's Cash flow Statement


Aurinia Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Aurinia Pharmaceuticals Inc earned $ 0.88 cash per share, on a free-cash flow basis 157.69 % of net earning per share.

Book value grew by 10.30 % sequentially to $2.69 per share, 4.54% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 2.66 per share from $ 2.41.

Company repurchased 1.52 million shares or 1.10 % in Sep 30 2025.
Interest Coverage Ratio was 10.14.

• More on AUPH's Dividends

 Market Capitalization (Millions) 2,088
 Shares Outstanding (Millions) 136
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 266
 Net Income (TTM) (Millions $) 78
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 48




Aurinia Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Aurinia Pharmaceuticals Inc had $ 0.88 cash flow per share, on a free-cash flow basis 157.69 % of net earning per share.

Book value grew by 10.30 % sequentially to $2.69 per share, 4.54% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 2.66 per share from $ 2.41.

Company repurchased 1.52 million shares or 1.10 % in Sep 30 2025.
Interest Coverage Ratio was 10.14.

• More on AUPH's Balance Sheets

 Market Capitalization (Millions) 2,088
 Shares Outstanding (Millions) 136
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 266
 Net Income (TTM) (Millions $) 78
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 48
   


  News about Aurinia Pharmaceuticals Inc Earnings

AUPH Soars: Aurinia Pharmaceuticals Inc. Shines in First Quarter Earnings Report

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has demonstrated impressive growth and improved financial performance during the first quarter of 2024, despite the challenges faced by many businesses in the Major Pharmaceutical Preparations sector. The company reported a decrease in loss per share, with $-0.07 per share compared to $-0.18 per share in the previous year. Additionally, income per share showed improvement from $-0.18 per share in the prior reporting season.
One of the key highlights of Aurinia Pharmaceuticals' performance was the significant jump in revenue, which increased by 46.191% to $50.30 million in the current reporting season from $34.41 million in the corresponding reporting season a ye...

Aurinia Pharmaceuticals Inc Witnessed an Astonishing 58.59% Surge in Revenue During Fiscal Q4 of 2023 - What's Driving Their Impressive Growth?

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) recently announced its fourth-quarter and full-year business performance for 2023, along with a strategic review update. The company has outlined its plans to enhance shareholder value by focusing exclusively on the commercial execution of its LUPKYNIS (voclosporin) business and implementing a significant share repurchase program.
In terms of financials, Aurinia reported a loss per share of $-0.18 for the fiscal period ending December 31, 2023, compared to $-0.17 in the previous year. The loss also surged from $-0.09 per share from the previous quarter. On the other hand, the company's revenue displayed robust growth, increasing by 58.59% to $45.10 million from ...

Aurinia Pharmaceuticals Inc Faces Challenges in Q3 2023: Revenue Declines and Growing Shortfall

The stock market is a dynamic and ever-changing environment, where investors closely monitor companies' financial performance in order to make informed decisions. In the third quarter of the 2023 earnings season, Aurinia Pharmaceuticals Inc faced some challenges that led to weakening orders and subsequent losses. However, it is important to view these results in context and consider the overall trajectory of the company.
During this reporting period, revenue for Aurinia Pharmaceuticals Inc declined by -2.266%, reaching $54.52 million. Additionally, the shortfall per share increased to $-0.09, compared to $-0.06 per share in the same period the previous year. These figures indicate a deterioration of the ...

Exceptional Q2 2023 Profits for Aurinia Pharmaceuticals: Surpasses Industry Peers with Crucial Revenue Spike!

Aurinia Pharmaceuticals Inc, a major player in the pharmaceutical preparations industry, has shown positive growth in several key areas, according to their recent financial reports. For the fiscal year ending June 30, 2023, the company reported a decrease in loss per share, from $-0.25 to $-0.08, compared to the previous year. Additionally, the company's earnings per share (EPS) improved from $-0.18 to $-0.08 during the same reporting period.
One of the most notable achievements for Aurinia Pharmaceuticals Inc is the significant increase in revenue. Their revenue jumped by an impressive 47.189% to $41.49 million, compared to $28.19 million in the previous year. This demonstrates a strong performance and ...

Aurinia Pharmaceuticals Inc Announces Remarkable Revenue Surge, Reflecting a 59.117% Increase in Latest Fiscal Period2. Impressive Revenue Growth and Decrease in Net Loss Propel Aurinia Pharmaceuticals Inc's Success in Recent Fiscal Period

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, recently reported their financial results for the most recent fiscal period, showing a decrease in their net loss from the previous year. The company reported a net loss of $-0.18 per share, compared to $-0.27 from the prior year. However, the shortfall increased from $-0.17 per share in the prior quarter.
Despite the decrease in net loss per share, there was significant revenue growth for Aurinia Pharmaceuticals. The company reported revenue of $34.41 million, representing a 59.117% increase from the corresponding quarter a year ago. The sequentially revenue also improved by 21.009% from $28.44 million. These growth figures are impressive, and th...


Date modified: 2025-11-11T18:36:00+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.